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Abstract  
Peanut allergy is one of the most prevalent and severe of food allergies with no available 
cure. The aim of this work was to evaluate the potential of an oral immunotherapy based 
on the use of a roasted peanut extract (PE) encapsulated in nanoparticles with 
immunoadjuvant properties. For this, a polymer conjugate formed by the covalent 
binding of mannosamine to the copolymer of methylvinyl ether and maleic anhydride 
was firstly synthetized and characterized. Then, the conjugate was used to prepare 
nanoparticles with an important capability to diffuse through the mucus layer and reach, 
iŶ a laƌge eǆteŶt, the iŶtestiŶal epitheliuŵ, iŶĐludiŶg PeǇeƌ͛s patĐhes. Theiƌ 
immunotherapeutic potential was evaluated in a model of pre-sensitized CD1 mice to 
peanut. After completing therapy, mice underwent an intraperitoneal challenge with PE. 
Nanoparticle-treatment was associated with both less serious anaphylaxis symptoms 
and higher survival rates than control, confirming the protective effect of this 
formulation against the challenge.  
 
Keywords: formulation; immunotherapy; mucosal immunization; oral drug delivery; 
nanoparticles; protein delivery; vaccine adjuvants 
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1. Introduction 
Food allergy is a serious and growing problem. For peanut allergic patients, they must 
maintain a strict allergen-free diet and carry emergency medication (i.e., epinephrine 
auto-injectors) to treat anaphylactic symptoms following accidental exposure 1. In spite 
of improvements in industrial cleaning procedures and food labelling, accidental 
exposures continue to be the leading cause of anaphylaxis 2. Particularly for young 
patients, the persistent fear to accidental exposures as well as the life-threatening 
reactions significantly disrupts their social and educational activities 3,4 This profoundly 
impairs health-related quality of life, to an extent greater than that seen in chronic 
conditions such as diabetes mellitus 5.  
Oral immunotherapy (OIT) has been suggested as a promising therapy for food allergy. 
OIT is based on the delivery of increasing doses of allergens with the objective of 
inducing desensitization and/or tolerance 6. The exact mechanism underlying 
desensitization is not well understood. Nevertheless, from an immunological point of 
view, OIT would induce allergen-specific IgG4 antibodies, reducing at the same time 
specific IgE 7. IgGϰ aĐts as a ďloĐkiŶg aŶtiďodǇ foƌ speĐifiĐ IgE, iŶhiďitiŶg IgE‐ŵediated 
mast cell activation and degranulation 8. This activation of mast cells produces the 
release of vasoactive amines and cytokines, responsible for the symptoms associated to 
allergic reactions.  
Different clinical trials have provided evidences that OIT can effectively desensitize a 
majority of individuals to a food allergen; although, the safety and tolerability of the 
conventional treatments continue to limit its use 9-11. Recently, in order to improve the 
efficacy and safety of conventional OIT, the use of polymer nanoparticles as allergen 
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delivery systems has been proposed 12. In principle, these devices may offer the 
following advantages: (i) protection of the loaded allergen from its premature 
degradation by the harsh conditions of the gut 13, (ii) co-encapsulation of 
immunomodulators to boost appropriate tolerogenic adaptive immune responses to 
allergens 14,15, and (iii) facilitate the presentation of the allergen to the GALT (gut 
associated lymphoid tissue) and promote a protective response 16,17.  
However, when polymer nanoparticles are orally administered, they are faced to the 
protective mucus layer that highly hampers their arrival to the intestinal epithelium 18,19. 
In fact, the mucus layer acts a as a barrier in which nanoparticles remain trapped by 
mucoadhesive forces and, thus, minimising their interaction with the immune cells 
localized in the intestinal epithelium 20. Among others, hydrophobic interactions 
between the surface of nanoparticles and hydrophobic domains of glycoproteins 
constituting the mucus play a major role in the mucoadhesion phenomenon 21. In order 
to minimize this drawback, different approaches have been proposed including the use 
of ͞slippeƌǇ͟ ŶaŶopaƌtiĐles. These ŶaŶoĐaƌƌieƌs, ǁith ŵucus-permeating properties, 
may be obtained by the coating or functionalization of nanoparticles with hydrophilic 
compounds, such as poly(ethylene glycols) 22 or poloxamers 23. Another interesting 
approach may be the functionalization of these nanoparticles with hydrophilic 
compounds with the capability of recognizing and binding to specific receptors localized 
on the surface of particular intestinal cells. In this context, the use of mannose modified 
nanoparticles may be a good strategy to target intestinal dendritic cells and M-cells of 
PeǇeƌ͛s patĐhes 24,25. 
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The aim of this work was the preparation and characterization of mannosamine-
modified nanoparticles as carriers for a peanut extract containing the main allergens. In 
the recent past, the nanoencapsulation of a peanut extract containing the main 
allergenic proteins (PE) in nanoparticles, from the copolymer of methyl vinyl ether and 
maleic anhydride (Gantrez® AN), displayed an important capability to induce a balanced 
Th1 and Th2 antibody response after one single dose 26. Specifically, mice treated with 
these nanoparticles displayed high levels of IFN-ɣ and IL-10 with lower pro-Th2 cytokines 
(IL-4, IL-5, IL-6) and reduced specific IgE levels compared to control 26. In the present 
work, the capability of nanoparticles based in a polymer conjugate between Gantrez® 
AN and mannosamine to carry this peanut extract and to offer protection against 
anaphylaxia in a peanut sensitized mice model was evaluated. Mannosamine was 
selected in order to improve the immunoadjuvant properties of Gantrez® AN 27 due to 
their capability to specifically bind and activate immune cells (i.e., dendritic cells and 
macrophages) 28,29. 
 
2. Methods 
2.1. Materials 
Poly(methyl vinyl ether-co-maleic anhydride) or poly(anhydride) (Gantrez® AN 119) was 
supplied by Ashland, (Ashland, USA). Peanut extract was kindly provided by Diater® 
Laboratories SA (Madrid, Spain). Ethanol and rose Bengal were provided by Panreac 
(Barcelona, Spain). Acetone was obtained from (VWR-Prolabo). Cholera toxin, D-
mannitol, D-mannosamine and Tween 20 were from Sigma-Aldrich (Germany). 
Lumogen® F red 305 was from Kremer (Aichstetten, Germany). Tissue-Tek® OCT 
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compound was obtained from Sakura (Alphen, Netherlands) 4´, 6-diamidino-2-
phenylindole (DAPI) was obtained from Biotium Inc. (Hayward, CA).  Micro-BCA™ 
Protein Assay Reagent Kit was from Pierce® (Rockford, USA). Veratox Peanut Kit was 
from Neogen (Lansing, MI, USA) and CAPITAN MANI® soft peanut butter was from 
Alimentación Varma, S.L. (Alcobendas, Madrid). Sodium hydroxide (NaOH) was from 
Scharlau (Spain).  
PLGA nanoparticles (PLGA-NP) were kindly supplied by Nanomi B.V. (The Netherlands). 
These nanoparticles displayed a mean size of 161 nm with a polydispersity index of 0.03 
and negative zeta potential of -29 mV.  
 
2.2. Peanut extract dialysis   
Prior the encapsulation in nanoparticles, the roasted peanut extract was dispersed in 
deionised water and transferred to a dialysis bag (MWCO 3500). The bag was introduced 
into a vessel with 15 mL water and maintained under agitation for 48 h at 8°C. Finally, 
the bag contents were transferred to vials and lyophilized in a Genesis 12 EL apparatus 
(Virtis, USA). For experimental studies, only the dialyzed peanut extract (PE) was used. 
The extract was characterized by SDS-PAGE and proteomic analysis in order to confirm 
the presence of the main allergenic proteins (Ara h1, Ara h2, Ara h3, Ara h5-8 and 
oleosins). 
 
2.3. Preparation and characterization of Gantrez® AN-mannosamine conjugate 
(GM) 
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The conjugate was formed by the covalent binding of mannosamine to the anhydride 
groups of the polymer backbone. For this purpose, 1 g Gantrez® AN [poly(anhydride)] 
was dissolved in 120 mL acetone. Then, 50 mg mannosamine were added and the 
mixture was heated at 50 ºC, under magnetic agitation at 400 rpm for 3 h. Then, the 
mixture was filtered through a pleated filter paper and the organic solvent was 
eliminated under reduced pressure in a Büchi R-144 apparatus (BÜCHI Labortechnik AG, 
Flawil, Switzerland) until the conjugate was totally dry. Finally, the resulting powder was 
stored at room temperature in a hermetically sealed container until use. 
For the characterization, GM was analysed by infrared spectroscopy, elemental analysis, 
1H-NMR and titration. The amount of mannosamine bound to the poly(anhydride) was 
estimated by the o-phthalaldehyde (OPA) method 30. More details about the 
characterization of GM are provided in the ͞Supplementary Material͟ section. 
 
2.4. Preparation of nanoparticles 
2.4.1. Preparation of unloaded nanoparticles (GM-NP) 
For the preparation of unloaded nanoparticles, 400 mg GM polymer was dissolved in 20 
mL acetone to form solution 1. Then 40 mL of a hydroalcoholic mixture (10 mL water 
and 30 mL ethanol) containing 80 µL calcium chloride (0.8% w/v) was added to solution 
1 where GM-NP nanoparticles were formed under continuous magnetic stirring.  The 
organic solvents were evaporated under reduced pressure (Rotary evaporator, Büchi R-
144, Switzerland) and the nanosuspensions were ultracentrifuged (Sigma 3K30 Rot. 
12150-H, UK) at 4ºC and 40,000 x g for 20 minutes.  Finally, the resulting batch of pellets 
was dispersed in 40 mL 2% mannitol solution  and dried by spray-drying in a Büchi Mini 
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Spray Drier B-290 apparatus (Büchi Labortechnik AG, Switzerland). The parameters for 
spray drying were: inlet temperature of 90 ºC, outlet temperature of 60 ºC, spray-flow 
of 600 mL/h, and aspirator at 100% of the maximum capacity. These nanoparticles were 
named GM-NP.  
As controls, nanoparticles based on Gantrez ® AN (NP) were prepared as described 
previously 31. 
2.4.2. Preparation of peanut extract-loaded nanoparticles 
Peanut extract-loaded nanoparticles were prepared by the dissolution of 400 mg GM in 
20 mL acetone. Then, 12 mg of the peanut extract (previously resuspended in 100 µL of 
purified water adjusted to a pH 3 with HCl 0.1N) was added to this solution and 
incubated, under agitation, for 45 minutes. Nanoparticles were obtained, purified and 
dried as described above. The resulting nanoparticles were identified as PE-GM-NP. 
2.4.3. Preparation of fluorescently labelled nanoparticles  
Nanoparticles were fluorescently labelled by the encapsulation of Lumogen® F Red 305. 
Briefly, 4 mg Lumogen Red was dissolved in a solution of acetone containing GM or 
Gantrez® AN polymer prior to the formation of the nanoparticles as described above. 
The resulting nanoparticles were purified and dried as described above. 
 
2.5. Physico-chemical characterization of nanoparticles 
For the characterization of nanoparticles, their size and zeta potential were determined 
by photon correlation spectroscopy (PCS) and electrophoretic laser Doppler 
anemometry, respectively, using a Zetaplus apparatus (Brookhaven Inst. Corp.). The 
yield of the preparative process of nanoparticles was calculated by gravimetry,31 
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whereas the amount of peanut encapsulated into nanoparticles was measured by using 
the bicinchonic acid method (microBCA). The surface hydrophobicity of unloaded and 
loaded nanoparticles was evaluated by the Rose Bengal test as previously described 32, 
with some minor modifications. Finally, the stability of nanoparticles was evaluated by 
measuring the turbidity changes as a function of time in buffer solutions with different 
pH value corresponded to simulated gastric and intestinal fluids SGF and SIF (i.e., pH 1.2 
and 6.8, respectively). More details about these studies are provided in ͞Supplementary 
Material͟. 
 
2.6. In vitro release   
The release studies were performed under sink conditions by using simulated gastric 
(SGF) and intestinal fluids (SIF), supplemented with Tween 20 (1% w/v). For these 
purpose, Float-A-Lyzer devices with a MWCO of 300 kDa (Spectrum Labs, Breda, The 
Nederlands) were used. First, the dialysis bags were washed with ethanol 10% for 10 
min and secondly, with water. The bags were filled with 96 mg formulation dispersed in 
5 mL SGF and then, placed into a vessel containing 660 mL SGF. The vessel was 
maintained under magnetic agitation and 200 µL samples were withdrawn at fixed time 
intervals and replaced with equal volumes of SGF. After two hours of incubation in SGF, 
the bags were transferred to a second vessel with 660 mL SIF. Again, at fixed times, 200 
µL were withdrawn and replaced with free SIF.  
The amount of PE released from nanoparticles was quantified with a sandwich enzyme-
linked immunosorbent assay (ELISA) kit for peanut allergy (Veratox®, Neogen, Scotland, 
UK). 
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2.7. In vitro evaluation of nanoparticles diffusion in mucus  
The diffusion of nanoparticles through porcine intestinal mucus barrier was measured 
by the Multiple Particle Tracking (MPT) technique to assess the permeation of particles 
through mucus barrier 33. MPT technique involves using of epifluorescence microscopy 
to Đaptuƌe ǀideos of paƌtiĐles͛ ŵoǀeŵeŶt ǁithiŶ the ŵuĐus saŵple folloǁed ďǇ tƌaĐkiŶg 
of particles trajectories of hundreds of individual particles within the mucus matrix 34. 
MeasuƌiŶg of paƌtiĐles͛ displaĐeŵeŶts eŶaďle us to ĐalĐulated diffusioŶ ĐoeffiĐieŶts of 
nanoparticles <Deff>. Diffusion of particles in water (Dº) were calculated by Stoke-
Einstein equation. The relative efficiency of nanoparticles diffusion (%<Deff>/ D° ratio) 
was calculated for comparison between particles restricted diffusion through mucus 
versus free movement in water. The ͞Supplementary Material͟ seĐtioŶ describes in 
detail these studies.  
 
2.8. Gastro-intestinal transit studies with radiolabelled nanoparticles  
Prior to in vivo studies, nanoparticles were labelled with technetium-99m by reduction 
with stannous chloride as described previously 35. All procedures were performed 
folloǁiŶg a pƌotoĐol pƌeǀiouslǇ appƌoǀed ďǇ the ͞EthiĐal aŶd BiosafetǇ Coŵŵittee foƌ 
‘eseaƌĐh oŶ AŶiŵals͟ at the UŶiǀeƌsitǇ of Naǀaƌƌa iŶ liŶe ǁith the EuƌopeaŶ legislatioŶ 
on animal experiments. These studies were carried out in male Wistar rats weighing 250-
300 g (Harlan, Barcelona, Spain). Animals were briefly stunned with 2% isoflurane gas 
(flow of oxygen of 0.2 L/min) for administration of nanoparticles by oral gavage, and 
then quickly awakened. Each animal received a single dose (1 mL) of nanoparticles (1 
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mCi; 0.8-1.0 mg with radiolabelled nanoparticles that were completed with up to 10 mg 
with unlabelled nanoparticles). For analysis, the animals were anaesthetised with 2% of 
isoflurane gas (flow of oxygen of 0.2 L/min) and placed in prone position on the gamma 
camera (Symbia T2 Truepoint; Siemens Medical System, USA). SPECT-CT images were 
acquired for 25 minutes, with the following parameters for SPECT: 128 x 128 matrix, 90 
images, 7 images per second and CT: 110 mAs and 130 kV, 130 images, slice thickness 3 
mm Fused images were processed using the Syngo MI Applications True D software. 
 
2.9. Biodistribution of nanoparticles within the gut 
These studies were carried out using a protocol described previously 22 with minor 
modifications, after approval by the ͞EthiĐal aŶd BiosafetǇ Coŵŵittee foƌ ‘eseaƌĐh oŶ 
AŶiŵals͟ at the UŶiǀeƌsitǇ of Naǀaƌƌa iŶ liŶe ǁith the EuƌopeaŶ legislatioŶ oŶ aŶiŵal 
experiments. Briefly, male Wistar rats (average weight 225 g; Harlan, Barcelona, Spain) 
were placed in metabolic cages and fasted overnight with free access to water. All 
animals received orally 10 mg of fluorescently labelled nanoparticles dispersed in 1 mL 
water. Then, after 2 hours the animals were sacrificed by cervical dislocation and the gut 
was removed. Different portions of the gut were collected, cleaned with PBS, stored in 
the tissue pƌoĐeediŶg ŵediuŵ OCT™ aŶd fƌozeŶ at -80°C. Each portion was then cut into 
5 µm sections on a cryostat and attached to glass slides. Finally, these samples were 
fixed with formaldehyde and incubated with DAPI (4,6-diamidino-2-phenylindole) for 15 
min before the cover assembly. The presence of both fluorescently loaded nanoparticles 
in the intestinal mucosa and the cell nuclei stained with DAPI were visualized in a 
fluorescence microscope (Axioimager M1, Zeiss, Oberkochen, Germany) with a coupled 
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camera (Axiocam ICc3, Zeiss, Oberkochen, Germany) and fluorescent source (HBO 100, 
Zeiss, Oberkochen, Germany). The images were captured with the software ZEN (Zeiss, 
Oberkochen, Germany). As control, an aqueous suspension of Lumogen® F Red 305 was 
administered. 
 
2.10. Protective study: sensitization, vaccination and challenge studies 
Experiments were performed using a protocol previously described 36,37 and in 
ĐoŵpliaŶĐe ǁith the ͞EthiĐal aŶd BiosafetǇ Coŵŵittee foƌ ‘eseaƌĐh oŶ AŶiŵals͟ at the 
University of Navarra in line with the European legislation on animal experiments. CD-1 
female mice of about 20 ± 1 grams were sensitized by orally administration of a mixture 
between of peanut butter (Capitan Mani® soft peanut butter; 4.35 mg with an approx. 
content of 1 mg protein) and 5 µg cholera toxin in a total volume of 200 µL of saline 
solution on days 1, 7, 15 and 21. Moreover a tape stripping was applied on the back of 
animals in order to obtain a higher sensitization. For this purpose, mice were shave and 
barrier-disrupted on back skin. Percutaneous sensitization in the damaged skin was 
performed by topical application of 100 µg peanut extract in 100 µL saline solution onto 
the barrier-disrupted skin.  
On day 25, the sensitized animals were divided in 3 groups of ca. 15 animals each. Each 
group of animals received one of the following treatments: (i) saline (Control +), (ii) free 
peanut extract dispersed in water (PE), and (iii) PE-loaded nanoparticles (PE-GM-NP). In 
addition, a group of non-sensitized animals were also employed as control (Control-). 
On days 25, 28 and 35 the animals received one oral dose of 1 mg peanut extract either 
resuspended in purified water (PE) or incorporated into nanoparticles (PE-GM-NP). 
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Finally, on days 44 or 45 animals were challenged by an injection of 2 mg PE in 200 µL of 
saline solution by intraperitoneal route in order to provoke an anaphylactic shock in the 
sensitized animals. Figure 1S (Supplementary Material) summarizes the protocol. 
In order to analyse the intensity of the anaphylaxis shock the following parameters were 
recorded: body temperature, mobility, bristly hair and cyanosis. Clinical anaphylactic 
reactions were scored by two independent observers. Piloerection and cyanosis were 
sĐoƌed as folloǁs: ;−Ϳ aďseŶt ;Ŷoƌŵal ŵouseͿ, ;+Ϳ ǁeak ƌeaĐtioŶ aŶd/oƌ sĐƌatĐhiŶg of the 
nose and head, (++) moderate, and (+++) strong. In a similar way, the mobility of animals 
was scored as very low (no reaction after pushing), low (arched back and low 
movements) or normal. 
 
2.11. Statistical analysis 
The physicochemical characteristics of nanoparticles as well as the in vitro studies were 
compared using the Student´s t test. For in vivo studies, comparisons were performed 
using the one-way analysis of the variance (ANOVA) and Tukey HSD test. In all cases 
p<0.05 was consider as a statistically significant difference. All calculations were 
performed using Graphpad Prism v6 (Graphpad Software, San Diego, CA). 
 
3. Results 
3.1. Synthesis and characterization of Gantrez-mannosamine conjugate (GM) 
Gantrez-mannosamine conjugate was synthesised by the covalent binding of 
mannosamine to the anhydride groups of the copolymer of methylvinylether and maleic 
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anhydride (Gantrez® AN). Figure 2S (Supplementary Material) shows a schematic 
representation of this synthesis.  
FTIR analysis, 1H-NMR analysis (Figures 3S and 4S; Supplementary Material) and titration 
(Table 1S; Supplementary Material) were also performed. From these studies it was 
calculated that the synthesis produced a polymer conjugate in which about 20% of the 
carboxylic acid groups from hydrated poly(anhydride) would be used for the covalent 
binding of mannosamine. In other words, the percentage of substitution means that 20 
molecules of the maleic anhydride groups of each 100 residues in Gantrez® AN had 
reacted with mannosamine to generate amide groups and carboxylic acids. From OPA 
analysis, the amount of mannosamine associated with the poly(anhydride) backbone 
was calculated to be about 21 µg/mg. Finally, with these data, the estimated MW of the 
conjugate (GM) was 97.54 kDa. 
 
3.2. Preparation of mannosamine-modified nanoparticles 
Nanoparticles were prepared from GM by a desolvation process using calcium as 
͞ďƌidge͟ ďetǁeeŶ tǁo ŶeighďouƌiŶg ĐaƌďoǆǇliĐ aĐid ƌesidues of the polǇŵeƌ ďaĐkďoŶe 
(Figure 2S). Table 1 shows the main physico-chemical properties of these nanoparticles. 
PE-loaded nanoparticles (PE-GM-NP) displayed a slightly higher mean size (270 nm vs 
190 nm) and a similar negative zeta potential (-33 vs. -37 mV) than unloaded ones (GM-
NP). Interestingly, the preparative process employed here resulted in homogeneous 
batches of nanoparticles (PDI lower than 0.2). The PE loading was calculated to be 25 
µg/mg nanoparticles with encapsulation efficiency of 80%. For fluorescently labelled 
nanoparticles, the amount of Lumogen® F Red 305 incorporated into the nanoparticles 
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was calculated to be similar for all the formulations tested and close to 7.3 µg/mg (data 
not shown).  
The surface hydrophobicity of nanoparticles was evaluated by using the Rose Bengal test 
(data not shown). From these studies, the hydrophobicity of GM-NP was 30-times lower 
than for Gantrez nanoparticles (NP). However, after encapsulation of PE, the resulting 
nanoparticles (PE-GM-NP) displayed a 6-times higher hydrophobicity than empty ones 
(GM-NP).  
The stability of nanoparticles was investigated by measuring the turbidity changes as a 
function of time in gastric (SGF) and intestinal (SIF) simulated fluids in a concentration 
of 3 mg/mL (Figure 1). Nanoparticles were easily dispersed in both media and no 
aggregation phenomenon were observed during the study. When incubated in SGF, both 
types of nanoparticles (loaded and empty) displayed a similar profile with a quite high 
stability for at least 1.5 h. In SIF, empty nanoparticles displayed a significantly higher 
stability than PE-loaded ones. Thus, for GM-NP, the turbidity of samples decreased 
during the first 30 min to reach a plateau of absorbance. At this moment, the turbidity 
of samples was about 70% of the initial values. For PE-GM-NP dispersed in SIF, the 
absorbance of samples decreased rapidly and after 90 min of incubation the absorbance 
was only of about 10% of the initial values. 
 
3.3. In vitro release studies 
Figure 2 shows the release profile of PE from GM nanoparticles as function of time when 
incubated in SGF (during the first 2 hours) and SIF (from 2 to 24 hours). In SGF only 
between 5-8% of the total payload of nanoparticles was released during the first 2 hours 
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of the experiment. In SIF, the release rate of PE from nanoparticles increased rapidly 
and, at the end of the experiment, all the PE content was released at the end of the 
experiment, as measured by ELISA. 
 
3.4. In vitro evaluation of nanoparticles diffusion in mucus   
Table 2 shows the diffusion coefficient in water (D°) calculated by the Stoke Einstein 
Equation, diffusion coefficient in the intestinal mucus <Deff> measured by the MPT 
technique and the ratio as percentage of these two parameters (Deff/D°) of the tested 
nanoparticles. This last parameter was employed to compare the diffusion of the 
nanoparticles in intestinal pig mucus after normalising the effect of particle size since D° 
is directly proportional to the particle size. GM-NP displayed a slightly higher diffusion 
coefficient than NP. For PE-loaded nanoparticles, the diffusion coefficient in the mucus 
was found to be about 12-fold higher than for unloaded nanoparticles prepared from 
the Gantrez-mannosamine (GM-NP). In all cases the relative efficiency of particles 
diffusion (Deff/D°) of these nanoparticles was higher than the diffusion of PLGA-NP 
control particles (0.0005 for PLGA-NP vs. 0.0190 and 0.2240 for GM-NP and PE-GM-NP 
respectively). 
 
3.5. Gastrointestinal transit studies with 99mTc radiolabelled nanoparticles 
Figure 3 shows the biodistribution (SPECT-CT images) of 99mTc-GM-NP orally 
administered to rats. One hour post-administration, an important fraction of the given 
dose of nanoparticles appeared to remain in the stomach of animals. Nanoparticles 
appeared to slowly enter in the small intestine and move along the gut over time. Likely, 
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at the end of the experiment, the no presence of radioactivity was observed in the liver 
or the lungs of the animals. 
 
3.6. Biodistribution of nanoparticles orally administered 
Figure 4 shows fluorescence microscopy images of ileum samples from animals treated 
with fluorescently labelled nanoparticles two hours post-administration. Empty 
nanoparticles (GM-NP) appeared to be mainly localized at the intestinal mucus layer 
(Figures 4A and 4B). On the other hand, PE-GM-NP displayed a higher capability for 
reaching the intestinal epithelium including the surface of Peyer´s patches (Figures 4C 
and 4D). As a control, an aqueous suspension of Lumogen was administered to rats (data 
not shown). In this case, Lumogen particles in gut were observed as long aggregates with 
no capacity to reach intestinal epithelium. 
 
3.7. Protective study 
Peanut sensitized animals received an immunotherapeutic schedule on days 4, 7, and 
14 after sensitization. Then, on day 20, animals were challenged with the intraperitoneal 
administration of 2 mg peanut extract. In order to analyse the intensity of the 
anaphylaxis, several parameters were evaluated. Ten minutes after challenge, 
sensitized- and non -treated animals (Control +) experienced an important decrease of 
their body temperature. Animals treated either with free (PE) or encapsulated (PE-GM-
NP) peanut extract displayed a significantly lower temperature variation (p<0.05).  
Thirty minutes after challenge, mice were visually assessed for symptoms of anaphylaxis 
and assigned symptoms scores (Table 3). Animals from the non-treated group (Control 
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+) displayed a low mobility and strong signs of bristly hair and cyanosis, whereas animals 
treated with free PE present a slightly better symptomatology, in spite of their 
apparently lower body temperature than control animals. On the contrary, animals 
treated with peanut-loaded nanoparticles displayed a better symptomatology in terms 
of cyanosis and decrease of rectal temperature and even a slightly better ability to 
maintain some movements than animals from the other groups. 
Figure 5 shows the cumulative survival of animals after the intraperitoneal 
administration of 2 mg PE. In the positive control group, 40 minutes after challenge, less 
than 10% of the animals were alive. On the other hand, for sensitized animals treated 
with PE, the survival rate was close to 30%, whereas for those animals treated with PE-
GM-NP, this survival rate was 53%.  
 
4. Discussion 
The success of nanoparticle-based formulations as oral carriers for biologically active 
compounds (e.g., peptides or proteins) is highly dependent on their capabilities to both 
protect the cargo against its premature degradation under the harsh conditions of the 
gut, and reach the ideal site for its absorption and/or action. Particularly, nanoparticles 
for allergy immunotherapy should be able to induce, modulate and potentiate an 
adequate immune response in order to minimize the effect associated with an allergen 
exposure in susceptible individuals. In this context, recent studies have shown that the 
encapsulation of a roasted peanut extract in poly(anhydride) nanoparticles down-
regulated the allergen-specific Th2 response, potentiating the specificTh1 response 26 
and, therefore, offering protection in a murine model of peanut allergy 37. 
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In order to ameliorate these results, one possible strategy may be the use of 
functionalization of these poly(anhydride) nanoparticles with ligands capable of offering 
mucus-permeating properties and the ability of specifically binding receptors on the 
immune cells localized in the gut. In this context, nanoparticles were prepared from a 
polymer conjugate obtained by the covalent binding of mannosamine to the copolymer 
of methylvinylether and maleic anhydride (Gantrez® AN). The new resulting 
nanoparticles (GM-NP) displayed a mean size slightly higher than those obtained from 
Gantrez® AN (193 vs 178 nm). On the other hand, the zeta potential of both types of 
nanoparticles were negative and quite similar in an absolute value (-37 vs -43 mV).  On 
the contrary, GM-NP displayed a 30-fold lower hydrophobic surface and a capability to 
diffuse in intestinal pig mucus of about 12-times higher than NP (Table 2). All of these 
evidences suggest that the hydrophilic residues of mannosamine would be mainly 
exposed on the surface of the nanoparticle. This idea is supported by previous works, 
where high diffusivity of particles was observed when they were coated with hydrophilic 
ligands 38,39. In line with this, the low stability of mannosylated nanoparticles in SIF 
(Figure 1), with an important decrease of their initial size, would facilitate their capability 
to cross the mucus layer and reach the intestinal epithelium. 
Regarding the in vitro properties of the peanut loaded nanoparticles, the release profile 
of PE from GM-NP was found to be dependent on the pH conditions (Figure 2). Thus, 
under simulated gastric conditions (pH 1.2), a small fraction (5-8%) of the loaded extract 
was released in two hours. On the contrary, under simulated intestinal conditions, the 
peanut content of nanoparticles was completely released in less than 24 hours of 
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incubation (Figure 2).  Likely, this behaviour is in line with the stability study of these 
nanoparticles in SGF and SIF (Figure 1). 
Furthermore, the encapsulation of PE increased the hydrophobicity of the resulting 
nanoparticles, evidencing the presence of components of this extract on the surface. 
Regarding the diffusion capabilities of nanoparticles in intestinal mucus, it was surprising 
to observe a significantly higher diffusivity for PE-loaded nanoparticles than for empty 
ones with a high hydrophilic character (Table 2). This result may be explained by a rapid 
release of peanut extract components located on the surface of the nanoparticles and 
their disturbing effects on the structural properties of the mucus gel. In fact, peanut 
proteins possess important emulsifying properties and oil binding capabilities 40 that 
may negatively affect to the viscoelastic properties of mucus 41. These effects, as well as 
their resistance to enzymatic degradation, would facilitate the ability of some peanut 
proteins (e.g., Ara h2, Ara h6, Ara h7, oleosins) to cross the mucus barrier and the 
intestinal epithelium, before exposition to underlying immune cells 42-44. 
Likely PE-GM-NP were able of reaching both the normal intestinal epithelium and the 
suƌfaĐe of PeǇeƌ͛s patĐhes ;Figuƌe 4). These findings are in agreement with previous 
results showing strong interactions of mannosylated nanocarriers within the intestinal 
epitheliuŵ, iŶĐludiŶg PeǇeƌ͛s patĐhes 25,45.   
Finally, the protective effect of PE-GM-NP therapy was evaluated in a model of pre-
sensitized mice to peanut. For this purpose, the animals were intraperitoneally 
challenged with the peanut extract. Animals treated with the PE-GM-NP displayed both 
a lower decrease in their basal temperature and less severe symptomatology associated 
with anaphylactic shock, when compared with animals treated with PE or ascribed to 
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the positive control group (Table 3). In line with these results, animals treated with PE-
GM-NP displayed a higher survival rate (53%) than animals treated with PE (35%) or the 
control group (6%) (Figure 5). In spite of the important differences, no statistical 
differences from the cumulative survival rate or mice treated with either PE or PE-GM-
NP was found. This lack of differences would be related to the limitations of our study, 
mainly associate with the number of animals involved in the study. Nevertheless, and 
based on the obtained results, the promising protective effect of PE-GM-NP observed in 
this study should be confirmed in a larger study involving a higher number of animals.  
In conclusion, nanoparticles based in a new Gantrez-mannosamine conjugate may be 
easily prepared by a desolvation procedure followed by a cross-linking process with 
calcium ions. These nanoparticles may be employed to load and carry a peanut extract, 
faĐilitatiŶg theiƌ ďiodistƌiďutioŶ ǁithiŶ the gut, iŶĐludiŶg PeǇeƌ͚s PatĐhes. In addition, 
this nanoparticle-based formulation offers an important protection against the effects 
induced by an anaphylactic shock in peanut sensitized animals. However, further studies 
are needed in order to corroborate the promising protection offered by PE-GM-NP in an 
experimental model of peanut allergy. 
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Figure captions 
Figure 1. Stability of empty (GM-NP) or peanut loaded nanoparticles (PE-GM-NP) in 
simulated gastric fluid (SGF, pH 1.2) or in simulated intestinal fluid (SIF, pH 6.8). Data 
expressed as mean ± SD (n=3). 
 
Figure 2. In vitro release of peanut extract from PE-GM-NP. Data expressed as 
cumulative amount of PE released versus time. Data expressed as mean ± SD (n=3). 
 
Figure 3. Volume rendered fused SPECT-CT images from representative rats at 1, 2 and 
4 hours after administration of 99mTc-labelled GM-NP by oral gavage. 
 
Figure 4. Fluorescent microscopic visualization of lumogen red-loaded nanoparticles 
(GM and PE-GM-NP) in longitudinal sections of the ileum of rats. Figures A and B 
correspond to empty formulations (GM-NP) whereas C and D refer to peanut-loaded 
nanoparticles (PE-GM-NP). The draw in the middle indicates the anatomical regions for 
the mucosal intestinal villi (M), the follicle-associated epithelium of Peyer`s Patches (PP), 
and Lumen (L). Arrows in figures indicate the intestinal portions with high interaction 
between nanoparticles and mucosal intestinal villi. DAPI staining of nuclei appears as 
blue. 
 
Figure 5. Cumulative survival rate of mice intraperitoneally challenge with peanut. 
Animals were treated with a peanut extract administered either free (PE) or 
encapsulated into nanoparticles (PE-GM-NP). Sensitized untreated animals (Control +) 
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and non-sensitized mice (Control -) were also included. (**p< 0.01, Log rank test 
indicates significant differences between animals treated with PE-GM-NP and non-
treated animals. Log rank test indicate significant differences between free peanut 
extract and non-treated animals *(p < 0.05). 
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Table 1. Physico-chemical characteristics of empty (GM-NP) and peanut loaded 
nanoparticles (PE-GM-NP). PDI: polydispersity index; PE: peanut extract; EE: 
encapsulation efficacy. Data expressed as mean ± SD (n=3). 
 
Formulation Mean size 
(nm) 
PDI Zeta 
potential 
(mV) 
Yield  
(%) 
PE 
loading 
(µg/mg) 
EE  
(%) 
GM-NP 193 ± 3 0.15 ± 0.01 -37 ± 4 87 - - 
PE-GM-NP 274 ± 2 0.16 ± 0.01 -33 ± 4 67 25 ± 2 81 ± 6 
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Table 2. Nanoparticle diffusion kinetics in intestinal pig mucus. Data expressed as mean 
± SD (n=3). D°: diffusion coefficient in water; <Deff>: diffusion coefficient in mucus; 
%<Deff>/ D° ratio: relative efficiency of particles diffusion; R: ratio of %<Deff>/ D° of the 
formulations tested. PLGA-NP: PLGA nanoparticles; GM-NP: empty nanoparticles; PE-
GM-NP: PE-loaded nanoparticles. 
 
 
D°  (water) 
cm2 x S-1 x 10-9 
<Deff>  (mucus) 
cm2 x S-1 x10-9 
%<Deff>/ D° 
ratio 
R 
PLGA-NP 27.91 0.0001 (± 0.0002) 0.0005 0.03 
NP 25.69 0.0004 (± 0.0003) 0.0016 0.084 
GM-NP 18.57 0.0035 (± 0.0018) 0.0190 1.00 
PE-GM-NP 23.79 0.0531 (± 0.0313) 0.2240 11.79 
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Table 3. Anaphylactic symptoms after allergic provocation challenge in peanut-
sensitized CD-1 mice. Animals were treated with a peanut extract administered either 
free (PE) or encapsulated into nanoparticles (PE-GM-NP). Sensitized untreated animals 
(Control +) and non-sensitized mice (Control -) were also included. 
 
Treatment ΔTemperature 
(ºC) 
Piloerection Mobility Cyanosis 
Control + -4.7 ± 2.6 +++ Very low +++ 
PE -5.2 ± 3.2 ++ Very low ++ 
PE-GM-NP -3.6 ± 2.7 ++ Low + 
Control - 0.5 ± 0.8 - Normal - 
Severity of the symptoms: (-) absent, (+) weak, (++) moderate, (+++) strong 
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Mannosylated nanoparticles for oral immunotherapy in a murine model of peanut 
allergy 
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Methods 
Characterization of Gantrez® AN-mannosamine conjugates  
The covalent insertion of mannosamine in the polymer chain was confirmed by infrared 
spectroscopy, elemental analysis, 1H-NMR and titration. The amount of mannosamine 
bound to the poly(anhydride) was estimated by the OPA method 1.  
IR analysis 
The binding between the poly(anhydride) and mannosamine was evaluated by Fourier 
transform infrared spectroscopy (FTIR). Spectra were collected in a Nicolet-FTIR Avatar 
360 spectrometer (Thermo/Nicolet 360 FT IR E.S.P., Thermo Fisher Scientific, Waltham, 
Massachusetts, USA), using a MKII Golden Gate ATR device with resolution of 2 cm-1 
connected with OMNIC E.S.P. software (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA). The spectrum obtained was an average of 32 scans. 
Elemental analysis 
The C, H, O and N contents of the synthesized conjugates were determined in a LECO 
CHN-900 apparatus (Michigan, USA). For this purpose, 1 mg of each polymer was 
analysed by triplicate and the results were expressed as percentage (% w/w). 
1H-NMR 
NMR spectra were obtained in a Bruker UltraShield NMR (400 MHz/54 mmA) Avance 
400 (Switzerland). For this purpose, an exactly weighed amount of samples were 
dissolved in deuterated DMSO and the spectra were obtained at ns = 6400. 
Titration 
The poly(anhydride) and its conjugate were first hydrated and dispersed in water till 
their total solubilisation. At this moment, the aqueous solutions of the polymers were 
titrated with NaOH 0.2N in the presence of phenolphthalein as indicator. Titration was 
used to measure the percentage of free carboxylic groups and to calculate the degree 
of substitution (DS) of the resulting conjugate. The decrease of the carboxylic groups in 
the polymer conjugates in comparison to unmodified Gantrez® AN evidenced the ligand 
binding. 
Mannosamine quantification 
The amount of mannosamine covalently attached to the poly(anhydride) was indirectly 
quantified by the O-phthalaldehyde (OPA) assay for primary amines. For this purpose, 
100 mg of unpurified GM were dissolved in 5 mL of acetone. Then, nanoparticles were 
obtained by the addition of 10 mL of a hydroalcoholic mixture (2.5 mL water and 7.5 mL 
Ethanol) containing 20 mL calcium chloride (0.8% w/v). The organic solvents were 
eliminated by evaporation under reduced pressure (Büchi R-144, Switzerland) and the 
resulting nanosuspension was centrifuged for 20 min at 40,000 x g (Sigma 3K30 Rot., 
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12150-H, UK). Supernatants were collected for quantification of the mannosamine 
content. 
The amount of mannosamine bound to the polymer backbone was estimated by 
difference between the initial amount of mannosamine added for the preparation of the 
conjugate and the amount of primary amines quantified in the supernatants.  
 
Physico-chemical characterization of nanoparticles 
Size, polydispersity index (PDI) and zeta potential 
The mean size and the zeta potential of nanoparticles were determined by photon 
correlation spectroscopy (PCS) and electrophoretic laser Doppler anemometry, 
respectively, using a Zetaplus apparatus (Brookhaven Instruments Corporation, 
Holtsville, USA). The diameter of the nanoparticles was determined after dispersion in 
ultrapure water (1/10) and measured at 25 ºC by dynamic light scattering angle of 90 
ºC. The zeta poteŶtial ǁas deteƌŵiŶed as folloǁs: ϮϬϬ μL of the saŵples ǁeƌe diluted iŶ 
2 mL of a 0.1 mM KCl solution adjusted to pH 7.4. The yield of the preparative process 
of nanoparticles was calculated by gravimetry 2. 
Surface hydrophobicity evaluation 
The surface hydrophobicity of unloaded and loaded nanoparticles was evaluated by the 
Rose Bengal test as previously described 3, with some modifications. Briefly, 200 µL of 
nanoparticle suspensions, with increasing concentrations of nanoparticles (from 0.03 to 
3 mg/mL), were mixed with 400 µL of a Rose Bengal aqueous solution (100 µg/mL). All 
samples were incubated under constant shaking at 1500 rpm, for 30 min at 25 ºC (Labnet 
VorTemp 56 EVC, Labnet International, Inc.). Afterwards, the samples were centrifuged 
at 13,500 x g for 30 min (centrifuge MIKRO 220, Hettich, Germany). The quantity of free 
RB in dispersion was determined by interpolation from a calibration curve. The 
concentration of RB bound to the nanoparticle surface was calculated as the difference 
between total concentration of RB used in the assay and free RB. Then, the 
hydrophobicity was calculated as the slope of the plot of partitioning quotient (PQ) vs. 
total surface area (TSA).  
Quantification of the peanut extract loaded in nanoparticles  
The amount of peanut encapsulated into nanoparticles was measured by using the 
bicinchonic acid method (microBCA). Briefly, 10 mg nanoparticles were resuspended in 
1 mL water and centrifuged at 40,000 x g (Sigma 3K30 Rot. 12150-H, UK) for 20 min. 
Then, the precipitate was dissolved in 1 mL NaOH 0.1N and kept for 1 h at 37 ºC with 
constant agitation. Samples were assay in triplicate and results of PE loading were 
expressed as the amount of PE (in µg) per mg nanoparticles whereas the entrapment 
efficiency (EE, expressed in %) was determined by relating the estimated total weight of 
proteins entrapped in the batch of nanoparticles to the initial weight of proteins initially 
added. 
Stability of nanoparticles in vitro  
The stability of nanoparticles was evaluated by measuring the turbidity changes as a 
function of time in buffer solutions with different pH value corresponded to simulated 
gastric and intestinal fluids (see below) SGF and SIF (i.e., pH 1.2 and 6.8, respectively). 
This analysis was performed on unloaded and loaded nanoparticles for more than 2 
hours in the SGF and SIF fluids.  
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Briefly, nanoparticles were firstly dispersed in purified water (6 mg/mL). Then, each 
suspension was mixed with a similar volume of either simulated gastric or intestinal fluid 
(1:1 v/v). The turbidity changes were monitored in a spectrophotometer at 405 nm in 
continuous kinetic measurements during 2 h (Labsystems EMS Reader MF). All 
measurements were performed by triplicate, and the results were expressed as 
percentage of absorbance reductions vs. time.  
 
In vitro evaluation of nanoparticles diffusion in mucus  
The diffusion of nanoparticles through porcine intestinal mucus barrier, as an in vitro 
measurement of their mucus-permeating properties, was assessed by Multiple Particle 
Tracking (MPT) technique. Mucus was isolated and standardized following the 
procedure described previously by Peason and coworkers 4,5. For this purpose, pig small 
intestines were obtained from a local abattoir immediately after slaughter and 
transported on ice to the laboratory. Sections of the intestines that did not visibly 
ĐoŶtaiŶ ĐhǇŵe ǁeƌe Đut iŶto ϭϱ Đŵ leŶgths aŶd ŵuĐus was removed. To remove the 
mucus gentle pressure was applied to one end of the length with the fingers and 
continuously applied unidirectionally to the opposite end.  Samples (0.5 g) of porcine 
intestinal mucus were incubated in glass-bottom MatTek imaging dishes at 37°C. The 
fluorescently labelled nanoparticles were inoculated into each 0.5 g mucus sample in a 
25 µL aliquot at a suspension concentration of 0.002% formulation. Each sample was 
incubated for 2 hours prior to video microscopy, in order to ensure effective particle 
distribution after inoculation. Video capture involved 2-dimensional imaging on a Leica 
DM IRB wide-field epifluorescence microscope (x63 magnification oil immersion lens) 
using a high speed camera (Allied Vision Technologies, UK) capturing 30 frames/second 
during 10 seconds (i.e. completed video film comprised 300 frames). For each 0.5 g 
mucus sample, a minimum of 300 individual trajectories were tracked and analysed. 
Videos were imported into Fiji ImageJ software to convert the movement of each 
nanoparticle into individual trajectories across the full duration of the 10 s videos. 
However, for the analysis of particle diffusion only a 30 frame video period (1 s) was 
used, with the criterion that any individual particle tracked must display a continuous 
presence in the X–Y plane throughout the respective 30 sequential frames. Limiting the 
period of analysis to 30 frames minimized the impact of mucin movement upon the 
particle diffusion calculations. The individual particle trajectories were converted into 
numeric pixel data (Mosaic Particle Tracker within Fiji ImageJ) which, based on the 
microscope and video capture settings, were converted into metric distance. The 
distances moved by every individual particle over time in the X–Y trajectory were then 
expressed as a squared displacement (SD). The mean square displacement (MSD) of any 
siŶgle paƌtiĐle ƌepƌeseŶts the geoŵetƌiĐ ŵeaŶ of that paƌtiĐle͛s sƋuaƌed displaĐeŵeŶts 
throughout its entire 30-frame trajectory. MSD was determined as follows: MSD = (X∆t  ) 2 + ሺY∆t  ሻ 2  
In any single mucus sample experiment an MSD was calculated for at least each of 100 
individual particles (i.e., 100 MSD calculations) with the experiment replicated a further 
two times for any particle type. The Effective Diffusion Coefficient (Deff) for a particular 
nanoparticle type was then calculated by: 
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Deff = MୗD4∗ ∆t  
where 4 is a constant relating to the 2-diŵeŶsioŶal ŵode of ǀideo Đaptuƌe aŶd Δt is the 
selected time interval. 
In order to compare the diffusion of nanoparticles after accounting the nanoparticles 
size the diffusion of all particles was also expressed as the parameter, % ratio [Deff]/[D°]. 
So that, diffusion coefficient (D°) in water was calculated by the Stokes–Einstein 
equation at a temperature of 37°C: D° = κ୘6πȠr   
IŶ ǁhiĐh κ is the BoltzŵaŶŶ ĐoŶstaŶt, T is aďsolute teŵpeƌatuƌe, Ƞ is ǁateƌ ǀisĐositǇ aŶd 
r is radius of the particle. 
 
Radiolabelling of nanoparticles 
Briefly, 1–2 mCi of freshly eluted 99mTc-pertechnetate was reduced with 0.03 mg/mL 
stannous chloride and the pH was adjusted to 4 with 0.1 N HCl. Then, 2 mg nanoparticles 
in 1 mL water and 99mTc were added to pre-reduced tin. The mixture was vortexed for 
30 s and incubated at room temperature for 10 min. The overall procedure was carried 
out in helium-purged vials. 
The radiochemical purity was examined by paper chromatography (Whatman 3MM) 
developed with NaCl 0.9%. The labelling yield was always over 90%. Then, the gastro-
intestinal fate of these radiolabelled nanoparticles was studied in male Wistar rats 
weighing 250-300 g that had fasted for 12 h.   
 
Protective study: sensitization, vaccination and challenge studies 
Figure 1S shows a schematic representation of the in vivo protective study. 
 
 
Figure 1S. Experimental protocol of the protective study. CD-1 mice were sensitized 
intragastrically (i.g) with peanut extract together with cholera toxin for 4 weeks. Then 
animals received the treatments (corresponding to 1 mg PE each) on days 25, 28 and 35. 
Peanut hypersensitive mice were treated i.g. with either free peanut extract (n=14) or 
encapsulated in PE-GM-NP (n=15) 1 mg/mouse/day in 0.4 mL water. In addition, a group 
of peanut allergic mice received only saline (control +, n= 16) and a group of non-
sensitized animals (control –, n=3) were monitored. 
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Results 
Synthesis and characterization of Gantrez-mannosamine conjugate (GM) 
GM was synthesised by the covalent binding of mannosamine to the anhydride groups 
of the copolymer of methylvinylether and maleic anhydride (Gantrez® AN) (Figure 2S). 
The figure also shows the effect of calcium as linker for the preparation of nanoparticles.  
 
 
 
Figure 2S. Schematic representation of the reaction between mannosamine and 
Gantrez® AN (A), and the effect of calcium used for the preparation of nanoparticles (B). 
R represents mannosamine. 
 
 
For the characterization of GM, FTIR analysis was performed to confirm the binding of 
the reactive functional groups of mannosamine (-OH or –NH2) to the anhydride groups 
of the polymer. Figure 3S shows the IR spectra for Gantrez® AN and GM. Both 
compounds presented bands at 1770-1850 cm-1 (Figure 3S, number 1), that are 
assoĐiated ǁith a tǇpiĐal υ;C=OͿ sigŶal ĐhaƌaĐteƌistiĐ of aŶhǇdƌide gƌoups. Foƌ GM, the 
IR spectra showed an additional peak at 1707 cm-1 (Figure 3S, number 2), corresponding 
to an amide group. This signal confirmed that mannosamine was bound to the Gantrez 
through the amine functional group (Figure 3S, number 3). This binding was also 
evidenced by elemental analysis (Table 1S). Thus, the binding of mannosamine to the 
polymer backbone slightly decreased the percentage of carbon, whereas the hydrogen 
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and oxygen content increased. In the same way, a very low amount of nitrogen was 
detected in GM samples (Table 1S). Finally, Figure 4S shows the 1H-NMR analysis of GM. 
 
 
Table 1S. Physico-chemical characterization of Gantrez® AN (G) and its conjugate with 
mannosamine (GM). For titration and OPA experiments, data expressed as mean ± SD 
(n=3). M: mannosamine. 
 
 C% H% O% N% 
% Free -
COOH 
DS 
(%) 
MW 
(kDa) 
Ligand 
content  
(µg M/mg) 
G 53.49 5.18 41.33 0 100  0 95.50 - 
GM 52.84 5.40 41.73 0.03 80.0 ± 0.7 20 97.54 20.90±0.84 
 
 
Figure 3S. IR spectra of Gantrez® AN polymer, mannosamine, and Gantrez® AN-
mannosamine conjugate. Number 1 shows the typical bands of the anhydride groups. 
Number 2 illustrates the band corresponding to C-N stretching. Number 3 shows the 
amide group formed by the binding of mannosamine to the poly(anhydride) chain. 
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Figure 4S. 1H-NMR spectra from Gantrez® AN and the conjugate between this copolymer 
and mannosamine (GM). 
 
  
a) Gantrez 
b) Gantrez-Mannosamine 
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